Soft Tissue Sarcoma (STS) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Players

Soft Tissue Sarcoma (STS) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Players
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 130+ key pharma and biotech companies are working on 130+ pipeline drugs in the Soft Tissue Sarcoma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The Soft Tissue Sarcoma therapeutics market is anticipated to evolve immensely in the coming years owing to the increased number of STS cases and the launch of emerging therapies in the market. Some of the key players involved in the development of novel drugs includes Arog Pharmaceuticals/Pfizer, Philogen S.p.A., Adaptimmune, and BioAtla.

Soft Tissue Sarcoma (STS) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Soft Tissue Sarcoma Market. 

The Soft Tissue Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Soft Tissue Sarcoma (STS) Pipeline Analysis

Soft Tissue Sarcoma (STS) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Soft Tissue Sarcoma and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Soft Tissue Sarcoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Infusion

  • Intra-arterial

  • Intradermal

  • Intralesional

  • Intratumoral

  • Intravenous

  • Oral

  • Parenteral

  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

  • Antibody

  • Antibody-drug conjugate

  • Cell therapy

  • Gene therapy

  • Immunotherapy

  • Nanoparticle

  • Peptide

  • Recombinant fusion protein

  • Small molecule

Mechanism of Action of the Emerging Pipeline Therapies

  • Antibody-dependent cell cytotoxicity

  • BRD9 protein degraders

  • Bromodomain and extraterminal domain protein inhibitors

  • Immunostimulants

  • DNA intercalators

  • Angiogenesis inhibitors

  • Fibroblast growth factor receptor antagonists

Learn How the Ongoing Clinical & Commercial Activities will Affect the Soft Tissue Sarcoma Therapeutic Segment @

Soft Tissue Sarcoma (STS) Therapeutics Landscape

There are approx. 130+ key companies developing therapies for Soft Tissue Sarcoma. Currently, Philogen is leading the therapeutics market with its Soft Tissue Sarcoma drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Soft Tissue Sarcoma (STS) Therapeutics Market Include:

Advenchen Laboratories, Aadi, Adaptimmune, AGC Biologics, Agenus, Amgen, Apexigen, AROG Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Athenex, AVEO Pharmaceuticals, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharma France, Clovis Oncology, CytRx, Daiichi Sankyo, Eli Lilly and Company, EMD Serono, Epizyme, Exelixis, Gem Pharmaceuticals, Genor Biopharma, GlaxoSmithKline, Gradalis, Incyte Corporation, Iovance Biotherapeutics, Jiangsu Hengrui Medicine, KaryoPharm Therapeutics, Loxo Oncology, Lytix Biopharma, MedImmune, Merck, Mirati Therapeutics, Morphotek (Eisai), Nanobiotix, NantCell, NantPharma, Novartis, Pfizer, PharmaMar, Philogen, Qbiotics, Roche Pharma AG, Sanofi, Taiho Pharmaceuticals, Tracon Pharmaceuticals, VasGene Therapeutics, and others.

Soft Tissue Sarcoma (STS) Emerging and Marketed Drugs Covered in the Report Include:

  • ADP-A2M4: Adaptimmune

  • AL3818: Advenchen Laboratories

  • BA3021: BioAtla

  • Crenolanib: Arog Pharmaceuticals

  • Durvalumab: AstraZeneca

  • Fibromun: Philagen S.P.A.

  • GPX-150: Monopar Therapeutics

  • L19 TNF: Philogen

  • Lenvatinib: Merck sharp & Dohme Corp.

  • LTX-315: Lytix Biopharma

  • NBTXR3: Nanobiotix

  • Nintedanib: Boehringer Ingelheim

  • Nivolumab: Bristol Myers Squibb

  • Yondelis (Trabectedin): Janssen Research & Development, LLC/Pharma Mar

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Soft Tissue Sarcoma Current Treatment Patterns

4. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Soft Tissue Sarcoma Late Stage Products (Phase-III)

7. Soft Tissue Sarcoma Mid-Stage Products (Phase-II)

8. Soft Tissue Sarcoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Soft Tissue Sarcoma Discontinued Products

13. Soft Tissue Sarcoma Product Profiles

14. Key Companies in the Soft Tissue Sarcoma Market

15. Key Products in the Soft Tissue Sarcoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Soft Tissue Sarcoma Unmet Needs

18. Soft Tissue Sarcoma Future Perspectives

19. Soft Tissue Sarcoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services and Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States